Literature DB >> 10595735

Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C.

S Kubo1, T Yamamoto, T Ikebe, T Shuto, K Hirohashi, H Tanaka, T Tsukamoto, K Wakasa, H Kinoshita.   

Abstract

The relationship between multicentric occurrence of hepatocellular carcinoma (HCC) and the histology of noncancerous hepatic tissue was investigated in 252 patients infected with hepatitis C virus (HCV) and surgically treated for HCC. One type of multicentric HCC had at least one tumor consisting of well-differentiated HCC, together with moderately or poorly differentiated HCC located in a separate region. The other type had an area of well-differentiated component around HCC with less differentiation in all occurrences. Noncancerous hepatic tissues were assessed using a histologic activity index score. Serum alanine aminotransferase (ALT) activity, the concentration of type 4 collagen, the grading score (severity of active hepatitis), and the staging score (degree of fibrosis) were significantly higher in patients with multicentric HCCs than in those without them. Platelet count was significantly lower in patients with multicentric HCCs. The prevalence of multicentric HCCs increased as the grading score and staging score increased. On univariate analysis, a low platelet count and high grading and staging scores were risk factors for multicentric HCCs. A high ALT activity and a high concentration of type 4 collagen tended to be risk factors. On multivariate analysis, high grading score and high staging score were independent risk factors. These findings indicate that active hepatitis and extensive fibrosis are responsible for the development of multicentric HCCs. Measurement of platelet count, ALT activity, and the concentration of type 4 collagen, and histologic assessment of noncancerous hepatic tissue provide information useful for estimation of the potential for multicentric carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595735      PMCID: PMC5926003          DOI: 10.1111/j.1349-7006.1999.tb00680.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  21 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C.

Authors:  S Miyagawa; S Kawasaki; M Makuuchi
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

3.  Management of new hepatic nodules detected by intraoperative ultrasonography during hepatic resection for hepatocellular carcinoma.

Authors:  N Kokudo; Y Bandai; H Imanishi; M Minagawa; Y Uedera; Y Harihara; M Makuuchi
Journal:  Surgery       Date:  1996-06       Impact factor: 3.982

4.  Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC.

Authors:  K Kenmochi; S Sugihara; M Kojiro
Journal:  Liver       Date:  1987-02

5.  Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen.

Authors:  T Ueno; S Inuzuka; T Torimura; H Oohira; H Ko; K Obata; M Sata; H Yoshida; K Tanikawa
Journal:  Scand J Gastroenterol       Date:  1992-06       Impact factor: 2.423

6.  Hepatic fibrosis in rats produced by carbon tetrachloride and dimethylnitrosamine: observations suggesting immunoassays of serum for the 7S fragment of type IV collagen are a more sensitive index of liver damage than immunoassays for the NH2-terminal propeptide of type III procollagen.

Authors:  L Ala-Kokko; V Günzler; J B Hoek; E Rubin; D J Prockop
Journal:  Hepatology       Date:  1992-07       Impact factor: 17.425

7.  Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC.

Authors:  K Tarao; S Takemiya; S Tamai; Y Sugimasa; S Ohkawa; M Akaike; H Tanabe; A Shimizu; M Yoshida; A Kakita
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

8.  Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis.

Authors:  S Ko; Y Nakajima; H Kanehiro; M Hisanaga; Y Aomatsu; T Kin; K Yagura; T Ohyama; K Nishio; K Ohashi; M Sho; T Yamada; H Nakano
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

9.  Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study.

Authors:  K Takenaka; E Adachi; T Nishizaki; K Hiroshige; T Ikeda; M Tsuneyoshi; K Sugimachi
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

10.  Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis.

Authors:  S Kubo; S Nishiguchi; K Hirohashi; T Shuto; T Kuroki; S Minamitani; T Ikebe; T Yamamoto; K Wakasa; H Kinoshita
Journal:  Jpn J Cancer Res       Date:  1998-04
View more
  13 in total

1.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

2.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

3.  Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis.

Authors:  S Kubo; A Tamori; K Ohba; T Shuto; T Yamamoto; H Tanaka; S Nishiguchi; K Wakasa; K Hirohashi; H Kinoshita
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 4.  Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.

Authors:  Jian-Hong Zhong; Qing-Lian Zhong; Le-Qun Li; Hang Li
Journal:  Tumour Biol       Date:  2014-08-14

Review 5.  Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus.

Authors:  Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takahiro Uenishi
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

6.  Surgical treatment for hepatocellular carcinoma detected after successful interferon therapy.

Authors:  Shoji Kubo; Hiromu Tanaka; Shigekazu Takemura; Satoshi Yamamoto; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Taichi Shuto; Kazuhiro Hirohashi
Journal:  Surg Today       Date:  2007-03-26       Impact factor: 2.549

Review 7.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

8.  Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score.

Authors:  Shoji Kubo; Hiromu Tanaka; Taichi Shuto; Shigekazu Takemura; Takatsugu Yamamoto; Takahiro Uenishi; Shogo Tanaka; Seikan Hai; Satoshi Yamamoto; Tsuyoshi Ichikawa; Shintaro Kodai; Kazuhiro Hirohashi
Journal:  J Gastroenterol       Date:  2005-10       Impact factor: 7.527

9.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

10.  Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.

Authors:  Atsushi Nanashima; Kenji Tanaka; Hiroyuki Yamaguchi; Shinichi Shibasaki; Shigeyuki Morino; Megumi Yoshinaga; Terumitsu Sawai; Tohru Nakagoe; Hiroyoshi Ayabe
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.